Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have ...
Researchers visualized ALK fusion proteins in real time. They showed that ALK inhibitors reshape flexible protein regions to ...
Researchers at Children's Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common ...
Investigators at Massachusetts General Hospital in Boston conducted an analysis of the fusion oncogene EML4-ALK and the more well-studied epidermal growth factor receptor (EGFR) mutation among a group ...
Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with Registrational Intent for TKI Pre-Treated Patients with ALK-Positive ...
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...
Durable activity of NVL-655 and zidesamtinib in heavily pre-treated patient populations supports ongoing Phase 2 investigation in earlier lines of treatment "Our development strategy has been anchored ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results